Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROMETH VC PLAIN vs ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Promethazine is a phenothiazine derivative that acts as a potent histamine H1 receptor antagonist, blocking allergic reactions; it also has anticholinergic, antiemetic, sedative, and local anesthetic effects.
Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.
FDA: Allergic conditions (rhinitis, urticaria, pruritus), motion sickness, nausea/vomiting, preoperative sedation, postoperative pain control (adjunct),Off-label: Nausea in pregnancy (morning sickness), vertigo, sedation in pediatric procedures
Management of mild to moderate pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate,Off-label: acute pain, chronic pain
Adults: 1-2 tablets (each containing Promethazine 6.25 mg and Phenylephrine 5 mg) orally every 4-6 hours; maximum 12 tablets per day.
1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Promethazine: terminal half-life 9-16 hours (mean 12 hours) in adults; longer in elderly (13.5-18 hours) and in hepatic impairment. Phenylephrine: half-life 2-3 hours.
Acetaminophen: 2-3 hours (normal), prolonged in hepatic impairment. Caffeine: 3-6 hours (adults), prolonged in liver disease or with oral contraceptives. Dihydrocodeine: 3.5-6 hours (terminal). Clinical context: q6h dosing interval appropriate; accumulation risk in renal/hepatic impairment.
Primarily hepatic metabolism via CYP2D6 and other pathways; metabolites include promethazine sulfoxide and N-demethylated derivatives.
Acetaminophen: primarily hepatic via glucuronidation and sulfation; minor CYP2E1, CYP1A2, CYP3A4. Caffeine: hepatic via CYP1A2. Dihydrocodeine: O-demethylation to dihydromorphine via CYP2D6; also via CYP3A4.
Primarily renal; promethazine is excreted in urine as unchanged drug (approximately 6%) and as metabolites (promethazine sulfoxide and N-demethylpromethazine); less than 1% excreted in feces. Phenylephrine is primarily metabolized by MAO and COMT; renal excretion of metabolites and unchanged drug (about 16%).
Acetaminophen: renal excretion of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%), <5% unchanged. Caffeine: renal excretion of metabolites (1-methyluric acid, 1-methylxanthine, etc.), <2% unchanged. Dihydrocodeine: renal excretion of metabolites (dihydrocodeine-6-glucuronide, nordihydrocodeine, dihydromorphine), ~20% unchanged. Overall, predominantly renal (≥85%), minor biliary/fecal.
Promethazine: approximately 93% bound to plasma proteins (mainly albumin). Phenylephrine: approximately 95% bound to plasma proteins (mainly albumin).
Acetaminophen: 10-25% (albumin). Caffeine: 25-36% (albumin). Dihydrocodeine: ~20-30% (albumin and α1-acid glycoprotein).
Promethazine: Vd 5-17 L/kg (mean ~12 L/kg), indicating extensive tissue distribution. Phenylephrine: Vd 4-5 L/kg, also widely distributed.
Acetaminophen: 0.7-1.0 L/kg. Caffeine: 0.5-0.8 L/kg. Dihydrocodeine: 1.0-1.5 L/kg. Clinical meaning: moderate distribution, potential for central nervous system penetration.
Oral promethazine: approximately 25% due to extensive first-pass metabolism. Intramuscular: nearly 100%. Rectal: approximately 70% of oral. Phenylephrine: oral bioavailability is low (about 38%) due to first-pass metabolism by MAO in gut and liver.
Acetaminophen: oral 75-85%. Caffeine: oral ~100%. Dihydrocodeine: oral ~20-30% (first-pass metabolism; extended-release formulations have altered bioavailability).
No specific guidelines; use with caution in renal impairment (Cr Cl <30 m L/min) due to potential accumulation of promethazine; consider dose reduction or extended intervals.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-30 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; avoid in severe impairment due to dihydrocodeine accumulation.
Child-Pugh Class A-C: Use with caution; reduce dose or avoid in severe hepatic impairment (Child-Pugh Class C) due to decreased metabolism of promethazine.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval to every 8 hours; Child-Pugh C: avoid use due to acetaminophen hepatotoxicity and dihydrocodeine accumulation.
Children aged 6-12 years: 1 tablet orally every 4-6 hours; maximum 6 tablets per day. Not recommended for children under 6 years due to risk of respiratory depression.
Not recommended for children under 12 years due to dihydrocodeine risks; for adolescents 12-18 years: 1 tablet orally every 4-6 hours as needed, maximum 4 tablets per day (weight-based dosing not established).
Elderly patients: Initiate at lower doses (e.g., 1 tablet orally every 6-8 hours) and titrate carefully; monitor for anticholinergic effects, sedation, and orthostatic hypotension.
Initiate with 1 tablet orally every 6 hours; caution due to increased sensitivity to opioids and hepatotoxicity from acetaminophen; maximum 4 tablets per day; monitor renal and hepatic function.
Promethazine should not be used in children younger than 2 years due to risk of respiratory depression, including fatalities. Use in children aged 2+ with caution. Not for intra-arterial or subcutaneous injection (risk of severe tissue injury).
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen can cause fatal hepatotoxicity; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of respiratory depression (especially in children, elderly, or with CNS depressants); use caution in asthma, sleep apnea, respiratory insufficiency. May impair cognitive/motor function; avoid alcohol. Extrapyramidal symptoms (rare). Caution in glaucoma, prostatic hyperplasia, urinary retention. Use in pregnancy (only if clearly needed).
Addiction, abuse, and misuse; respiratory depression; acetaminophen hepatotoxicity; drug interaction with benzodiazepines and CNS depressants; neonatal opioid withdrawal syndrome; risk of serotonin syndrome; severe hypotension; adrenal insufficiency; use in patients with head injury or increased intracranial pressure; seizures; avoid in patients with severe hepatic impairment.
Hypersensitivity to promethazine or phenothiazines; children <2 years; comatose patients; CNS depression (e.g., alcohol, barbiturates); Reye's syndrome (avoid in children with viral illness due to risk of Reye's? – actually contraindicated in patients with suspected Reye's). Also contraindicated for intra-arterial or subcutaneous injection.
Hypersensitivity to any component; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen; concomitant use with MAOIs or within 14 days; severe hepatic impairment.
No clinically significant food interactions. However, taking with food may reduce gastrointestinal upset. Avoid grapefruit juice as it may theoretically increase sedation.
Avoid alcohol; may increase risk of hepatotoxicity and CNS depression. High-fat meals may delay absorption but do not significantly affect overall exposure. Caffeine-containing foods and beverages may increase stimulant effects.
First trimester: Avoid. Inadequate studies; animal studies not sufficient. Second/third trimester: Use only if clearly needed; may cause neonatal respiratory depression, irritability, and tremors if used near term.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data on malformations. Dihydrocodeine: Opioid; first trimester: increased risk of neural tube defects (OR 2.0-2.5); third trimester: risk of neonatal opioid withdrawal syndrome (NOWS). Overall, combination product should be used only if benefit outweighs risks.
Promethazine is excreted into breast milk in small amounts; M/P ratio unknown. Caution suggested; avoid in infants with apnea, respiratory issues, or in mothers of preterm infants.
Acetaminophen: Excreted in breast milk (M/P ratio ~0.9); safe at therapeutic doses. Caffeine: Excreted (M/P ~0.5-0.8); moderate intake (<300 mg/day) generally safe. Dihydrocodeine: Excreted in low levels; however, interindividual variability in metabolism (CYP2D6) may lead to higher morphine concentrations in some infants; risk of neonatal respiratory depression. M/P ratio not well established for dihydrocodeine. Use with caution, monitor infant for sedation and feeding difficulties.
No standard dose adjustment required during pregnancy. Use lowest effective dose; monitor for increased sedation and anticholinergic effects due to physiological changes.
No specific dose adjustments for pregnancy due to lack of pharmacokinetic studies for this combination. However, note: Increased clearance of acetaminophen in pregnancy may require higher doses for analgesia but remains within standard limits. Caffeine clearance decreases in third trimester; consider reducing intake to <200 mg/day. Dihydrocodeine: Increased volume of distribution and clearance in pregnancy; dose may need titration but no established guidelines. Use lowest effective dose for shortest duration.
Promethazine is a phenothiazine derivative with antihistamine, antiemetic, sedative, and anticholinergic properties. Administer deep IM if parenteral route required; avoid intra-arterial or subcutaneous injection due to risk of severe tissue damage. Monitor for extrapyramidal symptoms in children and elderly. Use with caution in patients with asthma, COPD, or sleep apnea due to respiratory depression risk. Do not use in children <2 years due to risk of fatal respiratory depression.
Dihydrocodeine is a prodrug requiring CYP2D6 metabolism to active metabolites; poor metabolizers may have reduced efficacy while ultrarapid metabolizers risk toxicity. Caffeine potentiates analgesia and may cause insomnia with evening use. Do not exceed 8 tablets per 24 hours due to acetaminophen hepatotoxicity risk. Use with caution in elderly and patients with renal impairment.
Do not drive or operate heavy machinery until you know how this medication affects you, as it can cause drowsiness and dizziness.,Avoid alcohol and other central nervous system depressants while taking this medication.,Take exactly as prescribed; do not exceed recommended dose or duration.,Contact your healthcare provider if you experience difficulty breathing, involuntary muscle movements, or signs of jaundice (yellowing of skin/eyes).
Take with food if stomach upset occurs.,Avoid alcohol and products containing acetaminophen to prevent liver damage.,Do not exceed 8 tablets in 24 hours.,May cause drowsiness; avoid driving or operating machinery until you know how this medication affects you.,If you have a history of drug dependence, use with caution as dihydrocodeine can be habit-forming.
No interactions on record
"The combination of chlordiazepoxide, a benzodiazepine that enhances GABAergic inhibition, and dihydrocodeine, an opioid agonist primarily at mu-receptors, results in additive central nervous system (CNS) depression. This synergy increases the risk of profound sedation, respiratory depression, coma, and death, particularly in vulnerable populations such as the elderly or those with pre-existing respiratory compromise. Concurrent use also elevates the potential for hypotension and psychomotor impairment, leading to falls or accidents."
"Reserpine depletes catecholamines in the central nervous system and peripheral adrenergic neurons, leading to reduced sympathetic outflow. Dihydrocodeine, an opioid agonist, can cause further central nervous system depression and hypotension. When combined, there is an additive risk of excessive hypotension, bradycardia, and profound sedation, potentially leading to falls or respiratory depression."
"Dihydrocodeine, an opioid analgesic, undergoes O-demethylation primarily via CYP2D6 to form dihydromorphine, which contributes to its analgesic effects. Clemastine, a first-generation antihistamine, is metabolized mainly by CYP2D6 as well. When co-administered, clemastine competitively inhibits CYP2D6, reducing the clearance of dihydrocodeine and decreasing the formation of the active metabolite dihydromorphine. This can lead to diminished analgesic efficacy and potentially increased levels of parent dihydrocodeine, heightening the risk of opioid-related adverse effects such as respiratory depression, sedation, and constipation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROMETH VC PLAIN vs ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, answered by our medical review team.
PROMETH VC PLAIN is a Antihistamine-decongestant combination that works by Promethazine is a phenothiazine derivative that acts as a potent histamine H1 receptor antagonist, blocking allergic reactions; it also has anticholinergic, antiemetic, sedative, and local anesthetic effects.. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is a Opioid Agonist that works by Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROMETH VC PLAIN and ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROMETH VC PLAIN is: Adults: 1-2 tablets (each containing Promethazine 6.25 mg and Phenylephrine 5 mg) orally every 4-6 hours; maximum 12 tablets per day.. The standard adult dose of ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is: 1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROMETH VC PLAIN and ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROMETH VC PLAIN is classified as Category C. First trimester: Avoid. Inadequate studies; animal studies not sufficient. Second/third trimester: Use only if clearly needed; may cause neonatal respiratory depression, irritabili. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is classified as Category D/X. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.